
ANG Lifesciences India Surges with Unprecedented Buying Interest, Hits Upper Circuit
2025-12-01 09:31:18ANG Lifesciences India has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, reflecting a rare scenario of sustained demand and no selling pressure, potentially signalling a multi-day circuit phenomenon.
Read MoreWhy is ANG Lifesciences falling/rising?
2025-11-29 01:02:50Short-Term Price Movement and Market Context ANG Lifesciences has recorded a consecutive three-day rally, accumulating a 15.67% return during this period. Today's session opened with a gap up of 4.95%, signalling strong buying interest at the outset. The stock outperformed its sector by 4.44% today, indicating relative strength compared to its peers. Intraday, the price fluctuated between a low of ₹25.70 and a high of ₹27.98, ultimately settling at the day's peak level. Despite this recent upswing, the stock's longer-term performance remains subdued. Year-to-date, ANG Lifesciences has declined by 37.39%, contrasting sharply with the Sensex's 9.68% gain over the same period. Over one year, the stock is down 37.82%, while the Sensex has advanced 8.43%. The three-year tre...
Read More
ANG Lifesciences India Sees Unprecedented Buying Interest Amid Upper Circuit Lock
2025-11-28 10:20:36ANG Lifesciences India has witnessed extraordinary buying momentum, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals intense demand and the possibility of a multi-day circuit scenario, drawing significant attention from investors and market watchers alike.
Read More
ANG Lifesciences India Sees Unprecedented Buying Interest, Hits Upper Circuit
2025-11-27 09:41:34ANG Lifesciences India has witnessed extraordinary buying momentum today, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon highlights intense demand and the possibility of a sustained multi-day circuit scenario, setting the stage for close investor attention in the Pharmaceuticals & Biotechnology sector.
Read More
ANG Lifesciences India Sees Extraordinary Buying Interest Amid Upper Circuit Scenario
2025-11-26 11:45:33ANG Lifesciences India has witnessed a remarkable surge in buying activity, with the stock hitting the upper circuit and registering only buy orders in the queue. This unusual market behaviour signals intense demand and the possibility of a multi-day circuit scenario, drawing significant attention from investors and market watchers alike.
Read More
ANG Lifesciences India Faces Intense Selling Pressure Amid Consecutive Losses
2025-11-25 10:20:55ANG Lifesciences India is experiencing severe selling pressure, with the stock registering a sharp decline of 4.99% today and no buyers visible in the order book. This marks the seventh consecutive day of losses, reflecting a sustained period of distress selling that has significantly impacted the stock’s performance across multiple time frames.
Read More
ANG Lifesciences India Faces Intense Selling Pressure Amid Consecutive Losses
2025-11-24 09:55:48ANG Lifesciences India is currently experiencing severe selling pressure, with the stock registering a lower circuit and an absence of buyers on the order book. The pharmaceutical and biotechnology company has seen a continuous decline over the past week, signalling distress selling and heightened market caution.
Read More
ANG Lifesciences India Faces Intense Selling Pressure Amid Consecutive Losses
2025-11-21 11:00:44ANG Lifesciences India is currently experiencing severe selling pressure, with the stock registering a fifth consecutive day of losses and no buyers visible in the order book. The pharmaceutical and biotechnology company’s shares have underperformed the broader market significantly, signalling distress selling and a challenging outlook for investors.
Read MoreHow has been the historical performance of ANG Lifesciences?
2025-11-15 00:11:59Answer: The historical performance of ANG Lifesciences shows a significant decline in net sales and profitability over the past few years. Breakdown: ANG Lifesciences experienced a decrease in net sales from INR 354.30 crore in March 2022 to INR 92.85 crore in March 2025. This downward trend is mirrored in total operating income, which fell from INR 354.30 crore in March 2022 to the same INR 92.85 crore in March 2025. The company's operating profit (PBDIT) also declined sharply, moving from a profit of INR 68.28 crore in March 2022 to a loss of INR 0.25 crore in March 2025. Profit before tax followed a similar trajectory, dropping from INR 53.50 crore in March 2022 to a loss of INR 15.70 crore in March 2025. Consequently, profit after tax also turned negative, going from a profit of INR 40.32 crore in March 2022 to a loss of INR 12.41 crore in March 2025. The company's total assets decreased from INR 286.7...
Read MoreCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
22-Jan-2026 | Source : BSEDisclosure under Reg. 74(5) of SEBI (DP) Regulations 2018.
Closure of Trading Window
22-Dec-2025 | Source : BSEClosure of Trading Window.
Board Meeting Outcome for Board Meeting Outcome For To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025
14-Nov-2025 | Source : BSEConsidered and approved the financial results for the quarter and half year ended 30th September 2025
Corporate Actions
No Upcoming Board Meetings
ANG Lifesciences India Ltd has declared 10% dividend, ex-date: 02 Nov 21
No Splits history available
ANG Lifesciences India Ltd has announced 1:4 bonus issue, ex-date: 13 Jul 22
No Rights history available